CONTACT US LOCATIONS HOME ABOUT VALEANT OPERATIONAL EXPERTISE INVESTOR RELATIONS CAREER OPPORTUNITIES Valeant's Allergan Proposal » Key Facts and History » Board of Directors & Management » Acquisition FAQ's » Valeant's Allergan Proposal » Corporate Governance » U.S. Healthcare Compliance Program » U.S. Assistance Programs » Partnerships » Conflict Minerals Statement » Locations » Contact Us Home » About Valeant » Valeant's Allergan Proposal On April 22, 2014 Valeant Pharmaceuticals proposed to combine with Allergan, Inc. Links to materials related to that proposal can be found below. Valeant press release (April 22) April 22 Valeant webcast presentation (printable version) Valeant responds to Allergan's rejection of merger proposal (May 13 press release) Valeant substanially increases merger proposal (May 28 press release) Valeant approach -- an enduring engine for growth (Printable May 28 webcast presentation) Valeant and Pershing Square make revised offer (May 30 press release) Revised offer for Allergan (Printable June 2 webcast presentation) Valeant's perspective on R&D (June 12 presentation) An unrivaled platform for growth and value creation (June 17 presentation) Clarification on assertions made about Valeant's business (June 23) Investor presentation regarding the Allergan special meeting process (July 18) Valeant contacts Quebec and U.S. regulators about Allergan's false and misleading statements (July 21) Clarifications on assertions made about Valeant's business (August 19) Clarifications on assertions made about Valeant's business (September 8) Pershing Square, Valeant and Allergan settle pending litigation before the Delaware Court of Chancery (September 16) Valeant provides update on Q3 results and sends letter to Allergan CEO and lead independent director (September 24) Copyright © 2014 Valeant. All rights reserved. PRIVACY POLICY TERMS & CONDITIONS SITEMAP